



*Keenan*<sup>®</sup>

Keenan Pharmacy Services  
San Joaquin Valley Insurance Authority  
(SJVIA)  
Consultants Report: 3<sup>rd</sup> Quarter 2023

# SJVIA- EmpiRx Health – 3<sup>rd</sup> Quarter 2023 Highlights

- SJVIA's total plan cost increased in Q3-2023 by 10.3% to \$6,302,932
  - Tulare: \$2,691,520 in Plan Cost
  - Fresno: \$3,611,411 in Plan Cost
  - The increase in plan spend can be attributed to an increase in Rx count.
- Specialty claims plan cost decreased in Q3-2023
  - Q3-2023 \$2,300,578 (Q3-2022 - \$2,646,878)
  - 635 Scripts filled in Q3-2023 (Q3-2022 – 609)
    - Tulare: 228
    - Fresno: 407
- Variable Copay Assistance (VCAP) Savings (May – September)
  - SJVIA Total Savings \$500,767
    - Tulare: \$214,932
    - Fresno: \$285,835
- Rebates:
  - Q1-2023 net rebate amount is \$1,154,820
  - Q2-2023 estimated net rebate amount is \$1,200,000

\*With the new contract, rebates will be paid within 100 days following the end of the applicable quarter. Previously 120 days.

- Clinical Savings:
  - SJVIA Tulare: Jan-June 2023, \$1,233,313.63
  - SJVIA Fresno: Jan-June 2023, \$2,031,847.26

## **KPS Audit**

KPS conducts a yearly financial audit of EmpiRx clinical savings, Average Wholesale Price (AWP) discounts and rebate performance against the client's aggregate contractual guarantees.



# Top Clinical Cost Drivers by Drug (Q1 – Q3 2023)

- OZEMPIC (ANTIDIABETICS)
  - 2023 Q1-Q3 ingredient costs: \$1,373,366.60
  - 285 Utilizers
- HUMIRA PEN (ANALGESICS - ANTI-INFLAMMATORY)
  - 2023 Q1-Q3 ingredient costs: \$1,064,419.15
  - 22 Utilizers
- WEGOVY (ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS)
  - 2023 Q1-Q3 ingredient costs: \$816,152.40
  - 198 Utilizers
- DUPIXENT (DERMATOLOGICALS)
  - 2023 Q1-Q3 ingredient costs: \$695,123.87
  - 35 Utilizers
- TRULICITY (ANTIDIABETICS)
  - 2023 Q1-Q3 ingredient costs: \$669,359.97
  - 122 Utilizers
- JARDIANCE (ANTIDIABETICS)
  - 2023 Q1-Q3 ingredient costs: \$419,342.96
  - 128 Utilizers
- EMPAVELI (HEMATOLOGICAL AGENTS - MISC)
  - 2023 Q1-Q3 ingredient costs: \$378,843.20
  - 1 Utilizers
- RYBELSUS (ANTIDIABETICS)
  - 2023 Q1-Q3 ingredient costs: \$354,855.93
  - 69 Utilizers
- FARXIGA (ANTIDIABETICS)
  - 2023 Q1-Q3 ingredient costs: \$343,610.44
  - 101 Utilizers
- RINVOQ (ANALGESICS – ANTI-INFLAMMATORY)
  - 2023 Q1-Q3 ingredient costs: \$327,160.11
  - 10 Utilizers
- Note: Specialty medications require a prior authorization before they can be filled.



# New Medications Available in the Market

- **Zepbound – Approved Nov 8<sup>th</sup> 2023**

- Approved for chronic weight management in adults
- Shares the same active ingredient as Mounjaro (FDA approved in 2022), which is approved for use in adults with Type 2 Diabetes
- This medication, like others in the weight loss category, will be subject to plan design and clinical programs such as clinical review and appropriate quantity limits to ensure safe and appropriate use and dosing
- Once Zepbound becomes available (anticipated for after Thanksgiving), it will flag as a New To Market medication
  - All New to Market medications are excluded until they undergo a review for placement onto formulary and clinical programs by the Pharmacy & Therapeutics (P&T) Committee. P&T Committee meets quarterly and is composed of independent Medical Doctors and Pharmacists
  - Zepbound will go for review in early 2024
- Preliminary annual cost is \$13,778, which is approximately 21.5% less than the annual \*WAC of Wegovy, the current market leader

- **Biosimilars for Humira**

- EmpiRx Health is a high adopter of biosimilars because they reduce costs on behalf of clients and patients while delivering the same health outcomes
- In the case of Humira biosimilars, with several clinically appropriate options available, EmpiRx added **two low list price products** as preferred to the formulary alongside Humira (adalimumab) \*WAC/Year: \$90,000
  - Hadlima (adalimumab-bwwd)
    - \*WAC/Year: \$13,500
  - Unbranded-Hulio (adalimumab-fkjp)
    - \*WAC/Year: \$13,000
- This will give prescribing physicians options to switch to a new agent if they feel their patient is a candidate, while preventing gaps in care or disruption of therapy for those who are successful with Humira. It will also provide patients and providers with the time they need to get comfortable with a new device and product
- No current utilizers of Humira biosimilars for SJVIA yet
  - Making proactive outreach to providers to educate about Humira biosimilars and facilitate a therapeutic switch if clinically appropriate

\*WAC – Wholesale Acquisition Cost

